About AXONIS Therapeutics
AXONIS Therapeutics is a company based in Cambridge (United States) founded in 2011 by Joanna Stanicka and Bob Yant.. AXONIS Therapeutics has raised $124 million across 10 funding rounds from investors including R3, ARE and HHS. AXONIS Therapeutics offers products and services including AXN-027 and KCC2 Platform.
- Headquarter Cambridge, United States
- Founders Joanna Stanicka, Bob Yant
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Axonis Therapeutics, Inc
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$124 M (USD)
in 10 rounds
-
Latest Funding Round
$115 M (USD), Series A
Oct 18, 2024
-
Investors
R3
& 21 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of AXONIS Therapeutics
AXONIS Therapeutics offers a comprehensive portfolio of products and services, including AXN-027 and KCC2 Platform. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
AXN-027 is developed as a first-in-class oral KCC2 potentiator that is intended for treating epilepsy, pain, and other central nervous system disorders by restoring functional inhibition.
The KCC2 platform is utilized for advancing drug development in neurobiology, drawing on years of expertise to address neurological conditions.
Unlock access to complete
Unlock access to complete
Funding Insights of AXONIS Therapeutics
AXONIS Therapeutics has successfully raised a total of $124M across 10 strategic funding rounds. The most recent funding activity was a Series A round of $115 million completed in October 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 10
- Last Round Series A — $115.0M
- First Round First Round
- Investors Count 22
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct, 2024 | Amount | Series A - AXONIS Therapeutics | Valuation | Cormorant Asset Management , VenBio | |
| Sep, 2024 | Amount | Grant - AXONIS Therapeutics | Valuation |
investors |
|
| Jun, 2023 | Amount | Grant - AXONIS Therapeutics | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in AXONIS Therapeutics
AXONIS Therapeutics has secured backing from 22 investors, including institutional and venture fund investors. Prominent investors backing the company include R3, ARE and HHS. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
A life sciences investment firm focused on novel therapeutics is operated.
|
Founded Year | Domain | Location | |
|
Biotech funding, drug development support, and investment in life sciences.
|
Founded Year | Domain | Location | |
|
Seed and early-stage therapeutics companies are invested in by MRLV.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by AXONIS Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - AXONIS Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Axonis Therapeutics Comparisons
Competitors of AXONIS Therapeutics
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Frequently Asked Questions about AXONIS Therapeutics
When was AXONIS Therapeutics founded?
AXONIS Therapeutics was founded in 2011 and raised its 1st funding round 8 years after it was founded.
Where is AXONIS Therapeutics located?
AXONIS Therapeutics is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Who is the current CEO of AXONIS Therapeutics?
Joanna Stanicka is the current CEO of AXONIS Therapeutics. They have also founded this company.
Is AXONIS Therapeutics a funded company?
AXONIS Therapeutics is a funded company, having raised a total of $124M across 10 funding rounds to date. The company's 1st funding round was a Grant of $299.76K, raised on Oct 24, 2019.
What does AXONIS Therapeutics do?
AXONIS Therapeutics was established in 2011 and is headquartered in Cambridge, United States. Drug discovery services are delivered within the biotechnology sector, focusing on therapeutic development. Operations encompass target identification, lead optimization, and preclinical testing for pharmaceutical clients. The company operates through its domain axonis.us, with leadership held by Joanna Stanicka as Co-Founder and CEO, and Bob Yant as Founder. Geographic emphasis remains on the U.S. market.
What products or services does AXONIS Therapeutics offer?
AXONIS Therapeutics offers AXN-027 and KCC2 Platform.
Who are AXONIS Therapeutics's investors?
AXONIS Therapeutics has 22 investors. Key investors include R3, ARE, HHS, Perceptive Advisors, and Christopher & Dana Reeve Foundation.